日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PYM1 limits non-canonical Exon Junction Complex occupancy in a gene architecture dependent manner to tune mRNA expression

PYM1以基因结构依赖的方式限制非经典外显子连接复合物的占据,从而调节mRNA表达。

Sanjeev, Manu; Woodward, Lauren A; Schiff, Michael L; Patton, Robert D; Myers, Sean; Paul, Debadrita; Bundschuh, Ralf; Singh, Guramrit

Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis.

阿巴西普和阿达木单抗治疗类风湿性关节炎的随机试验中 ACPA 精细特异性和基因表达的差异性变化

Jabado Omar, Maldonado Michael A, Schiff Michael, Weinblatt Michael E, Fleischmann Roy, Robinson William H, He Aiqing, Patel Vishal, Greenfield Alex, Saini Jasmine, Galbraith David, Connolly Sean E

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT

更正:乌帕替尼可改善对传统合成疾病修饰抗风湿药物反应不足的类风湿关节炎患者的患者报告结局:SELECT-NEXT 研究结果

Strand, Vibeke; Pope, Janet; Tundia, Namita; Friedman, Alan; Camp, Heidi S; Pangan, Aileen; Ganguli, Arijit; Fuldeore, Mahesh; Goldschmidt, Debbie; Schiff, Michael

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis

类风湿性关节炎患者接受巴瑞替尼治疗2年后,关节结构损伤的放射学进展率较低

van der Heijde, Desirée; Schiff, Michael; Tanaka, Yoshiya; Xie, Li; Meszaros, Gabriella; Ishii, Taeko; Casillas, Marta; Ortmann, Robert A; Emery, Paul

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

乌帕替尼对患者报告结局的影响:SELECT-BEYOND 研究结果,这是一项针对对生物制剂类疾病修饰抗风湿药物反应不足的类风湿关节炎患者的 3 期随机试验。

Strand, Vibeke; Schiff, Michael; Tundia, Namita; Friedman, Alan; Meerwein, Sebastian; Pangan, Aileen; Ganguli, Arijit; Fuldeore, Mahesh; Song, Yan; Pope, Janet

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT

Upadacitinib 可改善对传统合成疾病修饰抗风湿药物反应不足的类风湿关节炎患者的患者报告结局:SELECT-NEXT 研究结果

Strand, Vibeke; Pope, Janet; Tundia, Namita; Friedman, Alan; Camp, Heidi S; Pangan, Aileen; Ganguli, Arijit; Fuldeore, Mahesh; Goldschmidt, Debbie; Schiff, Michael

Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)

阿巴西普和阿达木单抗治疗具有多种不良预后因素的早期类风湿关节炎患者的疗效:一项随机对照临床试验的事后分析(AMPLE)

Fleischmann, Roy; Weinblatt, Michael; Ahmad, Harris; Maldonado, Michael A; Alemao, Evo; Ye, June; Schiff, Michael

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics

基线特征与类风湿关节炎患者对传统合成DMARDs疗效不佳时,巴瑞替尼治疗的疗效之间的关系

Kremer, Joel M; Schiff, Michael; Muram, David; Zhong, Jinglin; Alam, Jahangir; Genovese, Mark C

Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort

早期未分化关节炎的临床和影像学病程与诊断时关节侵蚀的数量无关:来自瑞士前瞻性观察队列研究的结果

Mueller, Ruediger B; Kaegi, Toni; Haile, Sarah R; Schulze-Koops, Hendrik; Schiff, Michael; von Kempis, Johannes

A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences

一项针对慢性炎症性疾病生物疗法依从性和持续性的文献综述,旨在确定相关的未满足需求、驱动因素和后果

Maniadakis, Nikos; Toth, Emese; Schiff, Michael; Wang, Xuan; Nassim, Maria; Szegvari, Boglarka; Mountian, Irina; Curtis, Jeffrey R